M&A Deal Summary |
|
---|---|
Date | 2014-09-04 |
Target | Allegro Diagnostics |
Sector | Healthcare Services |
Buyer(s) | Veracyte |
Deal Type | Add-on Acquisition |
Deal Value | 21M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2006 |
Sector | Life Science |
Employees | 815 |
Revenue | 361M USD (2023) |
Veracyte is a molecular cytology company. Veracyte seeks to use molecular cytology to improve diagnosis with the promise to help physicians and patients make more informed treatment decisions. Veracyte solution will utilize molecular biomarkers on cytology samples to characterize nodules as benign or suspicious of malignancy. Veracyte was founded in 2006 and is based in South San Francisco, California.
DEAL STATS | # |
---|---|
Overall | 1 of 4 |
Sector (Healthcare Services) | 1 of 1 |
Type (Add-on Acquisition) | 1 of 4 |
State (Massachusetts) | 1 of 1 |
Country (United States) | 1 of 3 |
Year (2014) | 1 of 1 |
Size (of disclosed) | 4 of 4 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-02-03 |
Decipher Biosciences
San Diego, California, United States Decipher Biosciences, Inc. is a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers. Decipher Biosciences is based in San Diego, California. |
Buy | $600M |